Pure formulas. American craft.
$39.99
Modified GRF(1-29) — GHRH analog with four amino acid substitutions for enhanced stability 30 amino acids · No Drug Affinity Complex (DAC) — shorter half-life, pulsatile release profile 99% pure (HPLC verified) · Third-party lab tested · CAS 863288-34-0 For in vitro GHRH receptor research only
View Certificate of Analysis
✓ In Stock
Description
CJC-1295 (No DAC) 5mg — Modified GRF 1-29
Native GHRH disintegrates in about seven minutes. DPP-IV enzymes clip it apart almost as fast as it can signal. CJC-1295 (No DAC) is the engineered answer — the same 1-29 amino acid GHRH fragment, but with four strategic substitutions at positions 2, 8, 15, and 27 that make it resistant to enzymatic degradation. The result: a half-life of 30 minutes to 2 hours instead of 7 minutes, without the sustained multi-day elevation that comes with DAC-modified variants.
Specifications
Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 Amino Acids 30 Molecular Formula C152H252N44O42 Molecular Weight 3367.88 g/mol CAS Number 863288-34-0 Form Lyophilized powder Quantity 5mg per vial
Mechanism
CJC-1295 binds GHRH receptors on pituitary somatotrophs, triggering adenylate cyclase, cAMP accumulation, PKA phosphorylation, and growth hormone vesicle release. The non-DAC form preserves pulsatile GH secretion patterns — closer to what endogenous GHRH produces — while the DAC version creates sustained, multi-day elevation. Published clinical data documents GH increases of 70-107% with IGF-1 elevations around 28% over 16-week observation periods (Khorram et al., JCEM, 1997; PubMed 9141541).
No DAC vs with DAC
The Drug Affinity Complex is a maleimidopropionic acid derivative that covalently binds serum albumin. With it: half-life jumps to 6-8 days, GH stays elevated constantly. Without it: half-life stays at 30 minutes to 2 hours, GH pulses naturally. Different tools for different research questions. Both available from Heritage Labs USA.
CJC-1295 + Ipamorelin
These two target different arms of the GH axis — GHRH receptor vs GHS-R (ghrelin receptor). Preclinical protocols routinely pair them to study dual-pathway somatotroph activation. The CJC-IPA blend combines both in a single vial.
Research applications
GHRH receptor binding kinetics and profiling Peptide stability analysis under buffered conditions Comparative GHRH analog studies (vs Sermorelin, Tesamorelin) GH pulsatility and secretion pattern research Dual-pathway studies when paired with GHS-R agonists
Frequently paired with
Ipamorelin 5mg — Also available as CJC-IPA Blend. AOD-9604 5mg — Body composition research.
Quality and testing
Third-party tested with mass spectrometry identity confirmation. Batch-specific COAs available.
Storage
Lyophilized: -20°C Reconstituted: 2-8°C, use within 30 days Protection: Shield from light and moisture; avoid freeze-thaw cycles
References
Clark RG, Robinson ICAF. Nature. 1985;314(6008):281-283. PubMed 2858818 Khorram O, et al. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed 9141541 Martin B, et al. Neuromolecular Medicine. 2005;7(1-2):3-36. Sinha DK, et al. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMC7108996
For laboratory research use only. Not for human or veterinary use.